How Will Patients Benefit?

There are numerous benefits for Canadian patients that accrue from the MCRN program. These are some of the major advantages highlighted:

• Increasing access to more trials, in more centres across Canada
• Allowing patients access to new molecules or treatment combinations not yet approved by Health Canada
• Allowing patients access to new molecules or treatment combinations that are not yet reimbursed by the government or private insurance
• Ensuring the patient voice is heard through patient representation on the Clinical Trial Steering Committee and the Protocol Review Committee
• Providing real-word evidence through the MCRN Canadian Multiple Myeloma Database to help guide clinical decision-making, ultimately improving patient outcomes
• Promoting coast-to-coast collaboration, allowing researchers quick access to shared findings and data allowing for improved diagnosis and optimal treatment management
• Hosting clinical research in Canada may accelerate new treatment approvals by government bodies, by providing real-world Canadian evidence and data